DEBT CONVERSION AGREEMENTDebt Conversion Agreement • October 29th, 2010 • Calypte Biomedical Corp • Laboratory analytical instruments
This Agreement (“Agreement”) is entered into between (1) Calypte Biomedical Corporation, a Delaware corporation with its principal place of business at 15875 SW 72nd Avenue, Portland, Oregon 97224, USA (“Calypte”) and (2) SF Capital Partners Limited, whose registered office is at 3600 South Lake Drive, St. Francis Wisconsin 53235 (“SF Capital”), effective as of July 9, 2010.
as Transferee) And Marr Technologies Asia Limited And Calypte Biomedical Corporation (as Transferors) Regarding Beijing Marr Bio-Pharmaceutical Co., Ltd. Equity Transfer Agreement July 1 , 2010Calypte Biomedical Corp • October 29th, 2010 • Laboratory analytical instruments
Confidential treatment has been requested as to portions of Sections 8 and 9 of this Exhibit, which have been omitted from this version and replaced by [***]. A complete version of this Exhibit has been filed separately with the SEC.
Dated July 2010Debt Agreement • October 29th, 2010 • Calypte Biomedical Corp • Laboratory analytical instruments • Delaware
